Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Cisplatin + Fluorouracil + Sugemalimab |
Indication/Tumor Type | esophagus squamous cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | esophagus squamous cell carcinoma | predicted - sensitive | Cisplatin + Fluorouracil + Sugemalimab | Phase III | Actionable | In a Phase III trial (GEMSTONE-304), treatment with Sugemalimab (CS1001) combined with chemotherapy (Platinol (cisplatin) and Adrucil (fluorouracil)) demonstrated safety in patients with esophagus squamous cell carcinoma (n=358), and in CD274 (PD-L1)-positive patients (IHC >=10%, n=154), resulted in improved median progression-free survival (7.0 vs 5.4 mo, HR=0.50) and median overall survival (15.7 vs 11.2 mo, HR=0.57) compared to the placebo plus chemotherapy cohort (n=78) (PMID: 38302715; NCT04187352). | 38302715 |
PubMed Id | Reference Title | Details |
---|---|---|
(38302715) | First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study. | Full reference... |